Site updated at Wednesday, 22 June 2016

Living with Dementia

Transdermal Rivastigmine

Drug Patch Gets OK for Severe Alzheimer’s

The FDA has expanded the indication for transdermal rivastigmine to include patients with severe Alzheimer’s disease.

The approval means that the transdermal agent is indicated for use in any Alzheimer’s patient, irrespective of disease stage or severity. The expanded indication is the first of its type for any Alzheimer’s drug, according to a statement… Drug Patch Gets OK for Severe Alzheimer’s   

Alzheimer’s Disease

ad prognosis1 - margaret thatcher1 - atypical antipsychotic drugs1 - amyloid precursor protein6 - alzheimer sufferer1 - sundowning2 - mmse1 - american delirium society1 - wernicke's syndrome10 - neurodegeneration2 - alzheimer treatment1 - memory loss20 - dementia care program1 - memantine1 - wernicke's encephalopathy4 - physical discomfort1 - aphasia4 - journal of alzheimer's disease2 - beta amyloid plaques1 - cause of alzheimer's1 - thiamin deficiency1 - neurologic disorder1 - dementiaantipsychotic drugs1 - atypical alzheimer disease1 - short-term memory problems1 - gradual degeneration1 - blood sugar3 - alzheimer's imaging agents1 - substantia nigra7 - ad diagnosing1 -